Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM. Simonneau G, et al. Among authors: meier c. Lancet Respir Med. 2016 May;4(5):372-80. doi: 10.1016/S2213-2600(16)30022-4. Epub 2016 Apr 8. Lancet Respir Med. 2016. PMID: 27067478 Clinical Trial.
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP. Humbert M, et al. Among authors: meier c. Ann Rheum Dis. 2017 Feb;76(2):422-426. doi: 10.1136/annrheumdis-2015-209087. Epub 2016 Jul 25. Ann Rheum Dis. 2017. PMID: 27457511 Free PMC article. Clinical Trial.
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL. Hoeper MM, et al. Among authors: meier c. Eur Respir J. 2017 Sep 9;50(3):1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep. Eur Respir J. 2017. PMID: 28889107 Free PMC article.
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM. McLaughlin VV, et al. Among authors: meier c. BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7. BMC Pulm Med. 2017. PMID: 29282032 Free PMC article. Clinical Trial.
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE.
Benza RL, Corris PA, Klinger JR, Langleben D, Naeije R, Simonneau G, Ghofrani HA, Jansa P, Rosenkranz S, Scelsi L, Thenappan T, Raina A, Meier C, Busse D, Hoeper MM. Benza RL, et al. Among authors: meier c. Int J Cardiol. 2020 Oct 15;317:188-192. doi: 10.1016/j.ijcard.2020.05.044. Epub 2020 May 24. Int J Cardiol. 2020. PMID: 32461118 Free article.
1,455 results